Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lillian R Klug

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Cell|February 11, 2017
PDGFRA Antibody for Soft Tissue SarcomaLillian R Klug, Michael C Heinrich
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2024
A Novel Human SDHA-Knockout Cell Line Model for the Functional Analysis of Clinically Relevant SDHA VariantsJason D Kent, Lillian R Klug, Michael C Heinrich
Drugs|January 6, 2023
TKI Treatment Sequencing in Advanced Gastrointestinal Stromal TumorsHomma M Khosroyani, Lillian R Klug, Michael C Heinrich
Pharmacology & Therapeutics|July 3, 2018
Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinasesLillian R Klug, Jason D Kent, Michael C Heinrich
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2021
Inhibition of KIT Tyrosine Kinase Activity: Two Decades After the First ApprovalLillian R Klug, Christopher L Corless, Michael C Heinrich
Expert Review of Molecular Diagnostics|March 21, 2017
Using molecular diagnostic testing to personalize the treatment of patients with gastrointestinal stromal tumorsAmber E Bannon, Lillian R Klug, Christopher L Corless, et al.
Nature Reviews. Clinical Oncology|February 26, 2022
New treatment strategies for advanced-stage gastrointestinal stromal tumoursLillian R Klug, Homma M Khosroyani, Jason D Kent, et al.
Molecular Cancer Therapeutics|September 26, 2014
Combination therapy for KIT-mutant mast cells: targeting constitutive NFAT and KIT activityAlison C Macleod, Lillian R Klug, Janice Patterson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2017
Biochemical, Molecular, and Clinical Characterization of Succinate Dehydrogenase Subunit A Variants of Unknown SignificanceAmber E Bannon, Jason Kent, Isaac Forquer, et al.
Oncogene|September 23, 2018
LMTK3 is essential for oncogenic KIT expression in KIT-mutant GIST and melanomaLillian R Klug, Amber E Bannon, Nathalie Javidi-Sharifi, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Cell|February 11, 2017
PDGFRA Antibody for Soft Tissue SarcomaLillian R Klug, Michael C Heinrich
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2024
A Novel Human SDHA-Knockout Cell Line Model for the Functional Analysis of Clinically Relevant SDHA VariantsJason D Kent, Lillian R Klug, Michael C Heinrich
Drugs|January 6, 2023
TKI Treatment Sequencing in Advanced Gastrointestinal Stromal TumorsHomma M Khosroyani, Lillian R Klug, Michael C Heinrich
Pharmacology & Therapeutics|July 3, 2018
Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinasesLillian R Klug, Jason D Kent, Michael C Heinrich
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2021
Inhibition of KIT Tyrosine Kinase Activity: Two Decades After the First ApprovalLillian R Klug, Christopher L Corless, Michael C Heinrich
Expert Review of Molecular Diagnostics|March 21, 2017
Using molecular diagnostic testing to personalize the treatment of patients with gastrointestinal stromal tumorsAmber E Bannon, Lillian R Klug, Christopher L Corless, et al.
Nature Reviews. Clinical Oncology|February 26, 2022
New treatment strategies for advanced-stage gastrointestinal stromal tumoursLillian R Klug, Homma M Khosroyani, Jason D Kent, et al.
Molecular Cancer Therapeutics|September 26, 2014
Combination therapy for KIT-mutant mast cells: targeting constitutive NFAT and KIT activityAlison C Macleod, Lillian R Klug, Janice Patterson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2017
Biochemical, Molecular, and Clinical Characterization of Succinate Dehydrogenase Subunit A Variants of Unknown SignificanceAmber E Bannon, Jason Kent, Isaac Forquer, et al.
Oncogene|September 23, 2018
LMTK3 is essential for oncogenic KIT expression in KIT-mutant GIST and melanomaLillian R Klug, Amber E Bannon, Nathalie Javidi-Sharifi, et al.
Pageof 2